secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2023-09-12T23:59:59+00:00
Accession:  0001193125-23-233432
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra posts slide deck with BEACON Phase 2 topline results for LYR-220 in CRS
----------------------------------------------------------------------------

- LYR-220 evaluated in Phase 2 BEACON study for chronic rhinosinusitis with/without polyps in patients with prior ethmoidectomy.
- Topline results posted as slide deck on Lyra investor website on Sept 12, 2023; no specific data included in this 8-K text.
- Study identifier NCT05035654 on clinicaltrials.gov; two-part, patient-blinded, randomized trial.
- No financial impact or guidance changes announced; materiality depends on the actual results not seen here.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000119312523233432/0001193125-23-233432-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000119312523233432/d536466d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-233432

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer